<- Go Home
Biofrontera AG
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. It also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive skin. The company has a license and supply agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.
Market Cap
EUR 16.4M
Volume
844.00
Cash and Equivalents
EUR 2.2M
EBITDA
-EUR 2.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
EUR 16.4M
Profit Margin
75.63%
52 Week High
EUR 12.18
52 Week Low
EUR 2.15
Dividend
N/A
Price / Book Value
0.92
Price / Earnings
-2.81
Price / Tangible Book Value
0.98
Enterprise Value
EUR 15.1M
Enterprise Value / EBITDA
-1.59
Operating Income
-EUR 2.8M
Return on Equity
14.71%
Return on Assets
-6.84
Cash and Short Term Investments
EUR 2.2M
Debt
EUR 927.0K
Equity
EUR 17.9M
Revenue
EUR 21.7M
Unlevered FCF
-EUR 4.3M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium